New chemo combo trial aims to shrink aggressive breast tumors
NCT ID NCT00066443
Summary
This study tested a combination of two chemotherapy drugs (epirubicin and docetaxel) along with a medication (pegfilgrastim) to help the immune system recover. It involved 93 women with locally advanced or inflammatory breast cancer who had not received prior cancer treatment. The goal was to find the safest, most effective dose and see how well the treatment shrank tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atlantic Health Sciences Corporation
Saint John, New Brunswick, E2L 4L2, Canada
-
CHA-Hopital Du St-Sacrement
Québec, Quebec, G1S 4L8, Canada
-
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9, Canada
-
Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.